1. Home
  2. QLGN vs SCNI Comparison

QLGN vs SCNI Comparison

Compare QLGN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • SCNI
  • Stock Information
  • Founded
  • QLGN 1996
  • SCNI 2003
  • Country
  • QLGN United States
  • SCNI Israel
  • Employees
  • QLGN N/A
  • SCNI N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • SCNI Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • QLGN Health Care
  • SCNI Health Care
  • Exchange
  • QLGN Nasdaq
  • SCNI Nasdaq
  • Market Cap
  • QLGN 2.8M
  • SCNI 3.2M
  • IPO Year
  • QLGN N/A
  • SCNI N/A
  • Fundamental
  • Price
  • QLGN $3.16
  • SCNI $2.20
  • Analyst Decision
  • QLGN
  • SCNI
  • Analyst Count
  • QLGN 0
  • SCNI 0
  • Target Price
  • QLGN N/A
  • SCNI N/A
  • AVG Volume (30 Days)
  • QLGN 10.7K
  • SCNI 1.1M
  • Earning Date
  • QLGN 08-13-2025
  • SCNI 08-14-2025
  • Dividend Yield
  • QLGN N/A
  • SCNI N/A
  • EPS Growth
  • QLGN N/A
  • SCNI N/A
  • EPS
  • QLGN N/A
  • SCNI N/A
  • Revenue
  • QLGN N/A
  • SCNI $658,000.00
  • Revenue This Year
  • QLGN N/A
  • SCNI N/A
  • Revenue Next Year
  • QLGN N/A
  • SCNI N/A
  • P/E Ratio
  • QLGN N/A
  • SCNI N/A
  • Revenue Growth
  • QLGN N/A
  • SCNI N/A
  • 52 Week Low
  • QLGN $2.85
  • SCNI $1.90
  • 52 Week High
  • QLGN $29.44
  • SCNI $8.92
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 32.55
  • SCNI 42.95
  • Support Level
  • QLGN $3.37
  • SCNI $2.12
  • Resistance Level
  • QLGN $3.70
  • SCNI $2.85
  • Average True Range (ATR)
  • QLGN 0.21
  • SCNI 0.20
  • MACD
  • QLGN -0.05
  • SCNI 0.00
  • Stochastic Oscillator
  • QLGN 0.00
  • SCNI 11.37

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Share on Social Networks: